Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTaking a break from Wegovy is possible, but the evidence is clear: weight regain begins quickly once semaglutide leaves your system. Most people recover a significant portion of lost weight within a year of stopping, because the medicine was managing biological appetite signals that don't simply switch off. That makes a planned break very different from just running out of pens. Wegovy is a prescription-only medicine, so any decision to pause, reduce or restart should be made with a clinician who knows your full picture, not a call you make alone mid-course.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is the biggest misconception our prescribers hear about structured Wegovy breaks. The idea that stepping away for a few weeks lets your body "consolidate" what it has lost, or that it protects you from side effects further down the line, is not supported by the clinical evidence. Semaglutide works by acting on GLP-1 receptors in the brain and gut to reduce appetite and slow gastric emptying. When you stop taking it, those effects wind down as the drug clears, and the appetite signals that were being blunted return. There is no biological lock-in of lost weight.
The STEP 1 trial, published in the New England Journal of Medicine, followed participants after the treatment period ended: by one year post-treatment, two-thirds of the weight that had been lost was regained on average. That figure comes from a controlled trial setting with structured support. Real-world breaks, taken unplanned, often show steeper regain. A break may occasionally be clinically necessary, for example around planned surgery or during pregnancy, but it is not a routine optimisation strategy. If you are thinking about one, the starting point is a conversation with your prescriber, not the calendar.
For broader context on how Wegovy works as a treatment, including what the medicine does and does not do, that page covers the mechanism in more depth.
Semaglutide has a half-life of roughly one week, which means the drug takes several weeks to fully clear after the last injection. In the early days of a break, many people notice little change. Appetite begins to increase noticeably in the second or third week for most, though this varies. Some people experience a brief return of nausea or digestive discomfort as levels fall, though this is less common than the GI effects seen on dose increases.
Weight regain typically accelerates after the first month. Fat mass tends to return faster than lean mass, meaning body composition can shift in an unfavourable direction even if the number on the scale is still below where you started. This is not unique to Wegovy — it reflects how the body defends its previous weight set-point, a well-studied phenomenon in obesity medicine. The NHS patient information on semaglutide is clear that this is a long-term treatment for a chronic condition, not a short course.
If your break is planned around surgery, the guidance from NHS England is to inform your anaesthetist and surgical team that you have been taking a GLP-1 medicine, because gastric emptying effects can persist briefly after the last dose. This matters for anaesthetic safety. You can read more about what taking Wegovy involves day to day, including how to time injections and what the ongoing routine looks like in practice.
There are circumstances where a pause makes clinical sense: severe and persistent side effects that haven't settled after titration, a planned surgical procedure, pregnancy or attempting to conceive, or a period where consistent refrigerated storage is not possible. If your pen lives in the fridge door and a two-week trip means no reliable cold chain, that is a practical conversation to have with your prescriber in advance rather than something to improvise on the day.
Restarting is not as simple as picking up where you left off. After any significant break, a clinician should review whether returning to the dose you were on is appropriate, or whether re-titrating from a lower starting point would be safer and better tolerated. Cost is sometimes a factor in break decisions too, and understanding what Wegovy costs privately in the UK alongside what is included in that price can help with longer-term planning.
The question of whether a break from semaglutide is the right call depends heavily on why you are considering it, and our full guide to taking a break from semaglutide walks through the most common reasons people pause and what the evidence says about each. Side effects, cost, a life event, or simply wondering whether you still need it, each has a different clinical answer. What they have in common is that a prescriber is the right person to work through it with. If you want a clearer picture of what a Wegovy break actually involves, including how long a pause typically lasts and what to expect on return, that page covers the practicalities in detail. If you are currently treated elsewhere and want a second clinical view, you can speak to our prescribers through a free consultation, a real clinician, reviewed the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.